RxDoctor Payments Data

Lawrence Zeidman, MD

Clinical Neurophysiology · Detroit, MINPI 1467608943

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (48.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Grifols USA, LLC at 25.8% of the total.

$31,425in general payments, 2019–2025

Across 63 payments — averaging $498.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Grifols USA, LLC$8K
  • Pfizer$6K
  • Argenx US, Inc.$6K
  • Janssen Scientific Affairs, LLC$5K
  • Akcea Therapeutics, Inc.$2K
  • Octapharma USA, Inc.$2K
  • plus $2K from 11 others
$75,605in research payments, 2019–2025

Across 9 payments — averaging $8400.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi US Services Inc.$58K
  • Takeda Pharmaceuticals U.S.A., Inc.$18K

What the payments were for

  • Consulting fees$15,26549%
  • Speaking & faculty fees$11,50137%
  • Travel & lodging$2,8699%
  • Food & beverage$1,6915%
  • Education$990%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical neurophysiology providers in Michiganto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$31,601
Medicare patients
140
Services billed
349

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5022$317,185
Gamunex-CImmune Globul G/Gly/Iga Avg 4612$44,085
Mycophenolate Mofetil34$6,701
Pyridostigmine Bromide34$2,622
Gabapentin104$2,088
Duloxetine Hcl35$1,093
Pregabalin44$682
Tizanidine Hcl25$543
Diazepam16$269
Prednisone31$198
Donepezil Hcl16$114

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$1,500$317,18522 claims
Grifols USA, LLCGamunex-C$8,110$44,08512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Michiganon file to place this against a meaningful peer group, so we don't.

Other clinical neurophysiology in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →